Poolbeg Pharma PLC (AIM:POLB)
London · Delayed Price · Currency is GBP · Price in GBX 7.90
+0.30 (4.00%)
Jun 16, 2026, 11:08 AM GMT
Poolbeg Pharma Company Description
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom.
The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza.
It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses.
Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
Poolbeg Pharma PLC
| Country | United Kingdom |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Jeremy Skillington |
Contact Details
Address: The Clubhouse Holborn London, EC4A 3AG United Kingdom | |
| Phone | 44 20 7183 1499 |
| Website | poolbegpharma.com |
Stock Details
| Ticker Symbol | POLB |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BKPG7Z60 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeremy Skillington | Chief Executive Officer |
| Ian O'Connell | Chief Financial Officer |
| Carol Dalton | Head of Investor Relations |